A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of 2 doses of centanafadine
sustained-release (SR) (200 mg and 400 mg total daily dose [TDD]) compared with placebo in
adults with moderate to severe binge eating disorder (BED).
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.